Aims Denosumab, a fully human monoclonal antibody directed against RANKL, has recently been introduced in the treatment strategy of giant cell tumour of bone (GCTB). Aim of this study was to investigate the phenotypical modifications induced by denosumab treatment in a series of 15 GCTB.
Denosumab treated giant cell tumour of bone: A morphological, immunohistochemical and molecular analysis of a series / Girolami, Ilaria; Mancini, Irene; Simoni, Antonella; Baldi, Giacomo Giulio; Simi, Lisa; Campanacci, Domenico; Beltrami, Giovanni; Scoccianti, Guido; D'Arienzo, Antonio; Capanna, Rodolfo; Franchi, Alessandro. - In: JOURNAL OF CLINICAL PATHOLOGY. - ISSN 0021-9746. - STAMPA. - 69:(2016), pp. 240-247. [10.1136/jclinpath-2015-203248]
Denosumab treated giant cell tumour of bone: A morphological, immunohistochemical and molecular analysis of a series
MANCINI, IRENE;Simi, Lisa;CAMPANACCI, DOMENICO ANDREA;BELTRAMI, GIOVANNI;Scoccianti, Guido;FRANCHI, ALESSANDRO
2016
Abstract
Aims Denosumab, a fully human monoclonal antibody directed against RANKL, has recently been introduced in the treatment strategy of giant cell tumour of bone (GCTB). Aim of this study was to investigate the phenotypical modifications induced by denosumab treatment in a series of 15 GCTB.I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.